达妥昔单抗β(Dinutuximab beta) - 药物靶点：GD2_在研适应症：神经母细胞瘤，高风险神经母细胞瘤，复发性神经母细胞瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

ISQETTE、迪妥昔单抗、APN 311

+ [8]

靶点

GD2

作用方式

抑制剂

作用机制

GD2抑制剂(唾液神经节苷脂GD2抑制剂)、ADCC(抗体依赖的细胞毒作用)、补体依赖的细胞毒性作用

治疗领域

肿瘤其他疾病

在研适应症

神经母细胞瘤高风险神经母细胞瘤复发性神经母细胞瘤+ [2]

非在研适应症-

原研机构

APEIRON Biologics GmbH

在研机构

Recordati Rare DiseasesEUSA Pharma, Inc.

Recordati SpA

+ [1]

非在研机构

APEIRON Biologics GmbH

BeOne Medicines Ltd.

Millmount Healthcare Ltd.

+ [2]

权益机构

BeOne Medicines Ltd.

Recordati SpA

Ligand Pharmaceuticals, Inc.

+ [3]

最高研发阶段批准上市

首次获批日期

欧盟 (2017-05-08),

高风险神经母细胞瘤复发性神经母细胞瘤难治性神经母细胞瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、附条件批准 (中国)、临床急需境外新药 (中国)、优先审评 (澳大利亚)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

Sequence Code 263366044H

来源: *****

Sequence Code 263366046L

来源: *****

关联

20

项与达妥昔单抗β 相关的临床试验

NCT07318831

/ Not yet recruiting临床2期IIT

A Phase II Trial of Chidamide Combined With Dinutuximab Beta, Irinotecan, and Temozolomide for Refractory or Relapsed Neuroblastoma in Children

This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma. The primary goal is to evaluate how well this regimen works to control the cancer, while the secondary goal is to closely monitor its safety and side effects in these young patients.

开始日期2025-12-31

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

NCT07375563

/ Recruiting临床3期IIT

Chemoimmunotherapy Combined With Autologous NK Cell Therapy for the Treatment of Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the most common and life-threatening extracranial tumor in childhood.
Patients with stage 4 high-risk NB is the subgroup with the poorest prognosis. Within this group, two subgroups with an extremely unfavorable disease course are distinguished: patients with a poor response to the induction phase of therapy (refractory disease) and patients with relapsed or progressive disease.
Nowadays, 10-15% of patients show a poor end-induction response, whereas achieving a good end-induction response associated with better long-term survival. Improvement of the response to induction therapy may contribute to better treatment outcomes in newly diagnosed high-risk NB patients and can be achieved by intensification of the induction phase to decrease the number of patients with refractory disease. Also intensification of the second-line therapy may contribute to better responses in patients with relapsed and progressive disease.
Protocol aimed to overcome heterogeneous tumor drug resistance through the synergistic interaction of cytostatic and immunobiological agents in combination with NK cell therapy.
This approach combines cytotoxic agents with anti-GD2 monoclonal antibodies (mAb) to enhance antitumor activity. Cultured, ex vivo-activated autologous NK cells are infused to compensate for effector cell depletion during therapy and to augment antibody-dependent cellular cytotoxicity (ADCC), potentially improving clinical outcomes.
This comprehensive approach opens novel prospects for enhancing treatment efficacy in patients with refractory and relapsed high-risk NB.
The expected outcomes of this protocol include a significant increase in therapeutic efficacy indicators - objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS), as well as in patient quality of life.

开始日期2025-11-19

申办/合作机构

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

NCT06839703

/ Not yet recruiting临床1期IIT

International Open-label Phase I Dose Escalation Study of Dinutuximab Beta in Combination With Vincristine/Doxorubicin/Cyclophosphamide and Ifosfamide/Etoposide in Pediatric, Adolescent, and Adult Patients With GD2-positive Ewing Sarcoma

The goal of the study is to investigate the feasibility, toxicity, and biological activity of the treatment with dinutuximab beta in combination with standard chemotherapy in EWS to give high-risk patients with a GD2 positiv pumor a benefit in treatment. Within the study is tested with three different dosages in a 3+3 design with three pre-defined dose levels.

开始日期2025-03-01

申办/合作机构-

100 项与达妥昔单抗β 相关的临床结果

登录后查看更多信息

100 项与达妥昔单抗β 相关的转化医学

登录后查看更多信息

100 项与达妥昔单抗β 相关的专利（医药）

登录后查看更多信息

72

项与达妥昔单抗β 相关的文献（医药）

2026-04-01·PEDIATRIC BLOOD & CANCER

The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma

Article

作者: Demirtshyan, Ester ; Howard, Scott C. ; Matthay, Katherine ; Hoveyan, Julieta ; Lowe, Jennifer ; Hylton, Jennifer ; Villanueva, Gabriella ; Guscott, Martin ; Lam, Catherine G. ; Papyan, Ruzanna ; Tamamyan, Gevorg ; Streby, Keri A. ; Tadevosyan, Emma

ABSTRACT:

Background:

Long‐term survival for high‐risk neuroblastoma has increased from 40% to 60% by optimizing chemotherapy, surgery, radiation therapy, and the addition of anti‐GD2 antibody therapy. However, the high cost of this antibody presents access issues globally. This study evaluates the availability, financial coverage, and barriers to accessing these therapies across diverse healthcare settings.

Methods:

An online survey collected data on demographics, treatment practices, financial coverage, regulatory status, and barriers to anti‐GD2 therapy. Fisher's exact test was used to compare categorical variables between high‐income countries (HICs) and low‐ and middle‐income countries (LMICs). A retrospective cost analysis estimated the financial burden of anti‐GD2 therapies using standardized dosing for a representative 3‐year‐old patient.

Results:

Responses came from 100 facilities in 80 cities and 59 countries. Anti‐GD2 therapy for frontline maintenance was available in 93% of HIC centers, but only 21% of LMIC centers; 65% of LMIC centers reported no access, while the remainder had limited or irregular availability ( p < 0.0001, Fisher's exact test). When unavailable, isotretinoin was most often used alone. Financial coverage differed significantly: HICs relied on government or insurance funding, while LMICs depended on out‐of‐pocket or non‐profit support. Cost analysis showed a full treatment course would cost approximately $192,750 for dinutuximab, $142,695 for dinutuximab beta, and $610,800 for naxitamab, highlighting the substantial financial burden these therapies impose.

Conclusion:

Global access to anti‐GD2 therapy is highly unequal. Strategic measures, including negotiations for reduced drug costs, research‐based access, and WHO Essential Medicines List inclusion, could help address these disparities.

2026-01-20·JOURNAL OF CLINICAL ONCOLOGY

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial

Article

作者: Jannier, Sarah ; De Wilde, Bram ; Moroz, Veronica ; Barone, Giuseppe ; Laidler, Jennifer ; Gambart, Marion ; Valteau-Couanet, Dominique ; Gerber, Nicolas U. ; Nysom, Karsten ; Gray, Juliet C. ; Burke, G. A. Amos ; Zwaan, C. Michel ; Schleiermacher, Gudrun ; Gallego, Soledad ; Weston, Rebekah ; Howell, Lisa ; Hobin, Dave ; Chastagner, Pascal ; Moreno, Lucas ; Murphy, Dermot ; Wheatley, Keith ; Tweddle, Deborah A. ; Chesler, Louis ; Firth, Charlotte ; Elliott, Martin ; López-Almaraz, Ricardo ; Vaidya, Sucheta ; George, Sally ; Marshall, Lynley V. ; Castellano, Aurora ; Ladenstein, Ruth ; Holt, Grace ; van Eijkelenburg, Natasha ; Ng, Antony ; Canete, Adela ; Makin, Guy ; Owens, Cormac ; Pearson, Andrew D.J. ; Rubio-San-Simon, Alba ; Yeomanson, Dan ; Thebaud, Estelle ; Gates, Simon ; Brichard, Benedicte ; Defachelles, Anne Sophie ; Kearns, Pam ; Corradini, Nadege ; McCarthy, Anthony

PURPOSE:

Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HR-NBL) remain dismal. Here, we investigate addition of the anti-GD2 monoclonal antibody, dinutuximab beta (dB), to temozolomide (T)-based chemotherapy.

MATERIALS AND METHODS:

Patients with RR-HR-NBL were randomly assigned in a 1:2 ratio to receive chemotherapy alone or chemotherapy with dB, given concurrently as a 7-day infusion (10 mg/m 2 /24 h). The trial had a factorial design, with some patients also randomly assigned between chemotherapy regimens (T v T-topotecan [TTo]). Crossover to dB with To/cyclophosphamide was allowed for patients randomly assigned to chemotherapy alone with disease progression (PD). The primary outcome was best objective response (complete or partial) rate (overall response rate [ORR]) during six cycles of treatment. Progression-free (PFS), overall survival (OS), and safety were secondary outcomes.

RESULTS:

Sixty-five patients were randomly assigned to chemotherapy alone (3 T, 19 TTo) or with dB (6 dBT, 37 dBTTo). The median age was 4 years; 28 and 37 patients had refractory and relapsed diseases, respectively. Baseline characteristics were balanced between arms. The ORR was 30.2% (13 of 43) and 18.2% (4 of 22) in dB and non-dB arms, the median PFS was 11.1 months (95% CI, 4.3 to 15.5) for dB patients and 3.8 months (95% CI, 1.9 to 7.9) for non-dB patients, respectively. The median OS was 25.7 months (95% CI, 11.4 to not reached [NR]) for dB patients and 17.1 months (95% CI, 7.6 to 54.6) for non-dB patients (upper 95% CI, NR in dB arm). Thirteen of 22 patients in the non-dB arm crossed over to dB with cyclophosphamide/To because of PD. Neurotoxicity was more common in the dB arm (grade 1 and 2: 26% v 9%, grade 3: 2.3% v 4.5%), but other toxicities were similar.

CONCLUSION:

Within a randomized phase II setting, results observed with addition of dB to T-based chemotherapy in RR-HR-NB warrant further evaluation.

2026-01-01·iScience

Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy

Article

作者: Callegari, Elisa ; Kebede, Valentina ; Angelico, Patrizia ; Dirksen, Uta ; Frapolli, Roberta ; Canesi, Simone ; Bello, Ezia ; Pellerani, Isabella ; Scanziani, Eugenio ; Pirona, Lorenza ; Meroni, Marina ; Malinverno, Matteo ; Biondi, Stefano

Ewing sarcoma is a rare and aggressive cancer of the bone and soft tissues primarily affecting children and young adults. Prognosis for patients with metastatic or recurrent disease remains poor despite intensive multimodal therapy, highlighting the need of novel therapeutic approaches. The disialoganglioside GD2 is highly expressed on Ewing sarcoma cells, making this tumor eligible for anti-GD2 immunotherapy with dinutuximab beta. Through in vitro and in vivo approaches, this study demonstrated that dinutuximab beta effectively suppressed tumor growth by 60% (p = 0.0135) and improved survival rate by 68% (p = 0.0006) in a mouse model xenograft. The combination therapy with doxorubicin demonstrated superior efficacy compared to monotherapy, with enhanced tumor suppression (86%; p = 0.0009) and an extension of survival rate (146%; p = 0.000025). This study showed that dinutuximab beta, particularly in combination with standard chemotherapy, offers a promising approach to improve outcomes for high-risk Ewing sarcoma patients, providing a more effective alternative to current treatments.

96

项与达妥昔单抗β 相关的新闻（医药）

2026-03-29

·药事纵横

126亿美元！一家罕见病药企拟被收购

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。 3月26日，意大利知名制药企业Recordati Industria Chimica e Farmaceutica S.p.A.（以下简称"Recordati"）正式确认，已收到来自英国私募股权公司CVC Capital Partners的收购要约，其提出每股52欧元报价，交易估值超过120亿美元（约126亿美元）。受此消息影响，Recordati股价周四在米兰证券交易所上涨4.8%。 CVC资本投资布局聚焦欧洲，截至今年2月已持有Recordati约47%股份，是其重要股东。Recordati深耕罕见病药物领域，产品管线丰富，核心产品包括治疗库欣病的Isturisa、针对特定神经母细胞瘤患者的Qarziba（尚未获美国上市批准，Recordati正推进获批工作），以及治疗罕见代谢性疾病的已上市药物Carbaglu。 Recordati成立于1926年，总部位于意大利米兰，是一家在欧洲证券交易所上市的国际制药集团，拥有超过4450名员工，主要产品包括治疗库欣综合征的Isturisa和神经母细胞瘤的Qarziba等18种罕见病药物。2025年全年营收26.18亿欧元，EBITDA达到9.91亿欧元。2024年营收23.42亿欧元，同比增长12.4%，其中罕见病业务增长显著。其在华子公司锐康迪已于2026年1月启动清算，终止中国市场业务。参考资料：公司官网

并购上市批准

2026-03-27

·精准药物

超120亿美元！意大利百年药企 Recordati 迎来收购邀约

3月26日，意大利知名制药企业Recordati Industria Chimica e Farmaceutica S.p.A.（以下简称"Recordati"）周四正式确认，已收到来自英国私募股权公司CVC Capital Partners的收购邀约，交易估值超过120亿美元。 CVC Capital Partners提出的非约束性收购意向为每股52欧元，旨在收购Recordati 53.18%的股权。受此消息影响，Recordati股价周四在米兰证券交易所上涨4.8%，投资者对这一潜在交易反应积极。 Recordati 是一家意大利百年制药巨头，成立于1926年，专注于罕见病药物研发。主要产品包括治疗库欣综合征的Isturisa和神经母细胞瘤的Qarziba等18种罕见病药物。2024年营收23.42亿欧元，同比增长12.4%，其中罕见病业务增长显著。其在华子公司锐康迪（北京）医药有限公司已于2025年12月11日启动清算程序，并于2026年1月9日发布公告，正式宣布全面退出中国。在全球，罕见病支付都是个难题。罕见病药研发成本高，使用人数少，定价高昂，支付往往依赖医保、商保在内的多层次支付体系。但基本医保基金往往需要兼顾常见病、慢性病等保障需求，很多罕见病药物价格高昂，仍在等待进入医保的过程中。此次收购若达成，将成为近年来欧洲制药行业规模最大的私募股权交易之一。CVC Capital Partners此前已于2018年以35亿美元收购Recordati的多数股权，此次全面收购将使其完全掌控这家意大利制药企业。分析师对Recordati前景持乐观态度。Jefferies给予该股"买入"评级，目标价为60.5欧元，并认为公司核心罕见病产品的销售峰值预期存在上调空间。 Recordati 最新披露的 2025 年全年业绩显示，公司在被提出收购要约前，已维持稳健的经营表现。财报显示，全年净收入达 26.18 亿欧元，同比增长 11.8%（按固定汇率为 8.3%）；EBITDA 为 9.91 亿欧元，同比增长 15.4%，利润率提升至 37.8%。调整后净利润为 6.51 亿欧元，同比增长 14.5%，而报告净利润为 4.44 亿欧元，同比增长 6.5%。现金流方面，自由现金流为 5.59 亿欧元，同比小幅增长；截至年末，净负债为 20.37 亿欧元，对应约 2.1 倍 EBITDA，整体杠杆水平保持在可控区间。整体来看，在本次收购要约提出之前，Recordati 已呈现出收入稳健增长、利润率持续提升的经营态势，这也在一定程度上解释了其在资本市场上的吸引力。目前，该收购要约尚处于非约束性阶段，交易的最终完成仍需经过尽职调查、董事会批准以及相关监管机构的审批程序。参考资料： [1] https://d2e3isjppdvvam.cloudfront.net/wp-content/uploads/2026/03/19165715/Board-approves-FY-2025-results.pdf [2] https://d2e3isjppdvvam.cloudfront.net/wp-content/uploads/2026/03/26135323/PRESS-RELEASE-REGARDING-MARKET-RUMOURS.pdf 声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

2026-03-26

·EndPoints

Recordati says it's received a $12B+ takeover bid

Milan-based Recordati confirmed Thursday that it has received a buyout offer north of $12 billion. The company said in a press release that private equity firm CVC Capital Partners has submitted an offer of €52 per share, equaling about $12.6 billion in total. Recordati said it has not yet reviewed the offer. CVC, which is headquartered in Luxembourg and primarily focuses on European investments, has a roughly 47% stake in Recordati as of February. Recordati has a portfolio of rare disease drugs including Isturisa for Cushing’s disease, an endocrine system disorder, and Qarziba for certain neuroblastoma patients. Qarziba is not approved in the US yet, though Recordati is pursuing approval. The company also sells the drug Carbaglu, which treats a rare metabolic disorder that causes high levels of ammonia in the blood. News of an imminent deal was first reported by Italian financial publication Il Sole 24 Ore earlier Thursday.

上市批准并购

100 项与达妥昔单抗β 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	达妥昔单抗β	L01XC16	DB09077

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
神经母细胞瘤	澳大利亚	Recordati Rare Diseases	2020-04-02
高风险神经母细胞瘤	欧盟	Recordati AG	2017-05-08
高风险神经母细胞瘤	冰岛	Recordati AG	2017-05-08
高风险神经母细胞瘤	列支敦士登	Recordati AG	2017-05-08
高风险神经母细胞瘤	挪威	Recordati AG	2017-05-08
复发性神经母细胞瘤	欧盟	Recordati AG	2017-05-08
复发性神经母细胞瘤	冰岛	Recordati AG	2017-05-08
复发性神经母细胞瘤	列支敦士登	Recordati AG	2017-05-08
复发性神经母细胞瘤	挪威	Recordati AG	2017-05-08
难治性神经母细胞瘤	欧盟	Recordati AG	2017-05-08
难治性神经母细胞瘤	冰岛	Recordati AG	2017-05-08
难治性神经母细胞瘤	列支敦士登	Recordati AG	2017-05-08
难治性神经母细胞瘤	挪威	Recordati AG	2017-05-08

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
平滑肌肉瘤	临床2期	德国	Recordati SpA	2021-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05373901 (CTgov)	临床1期	高风险神经母细胞瘤	8	Dinutuximab Beta+13-cis-retinoic acid	顧壓鏇醖選願願積齋淵 = 製網繭夢衊憲簾夢願遞襯鏇觸築衊齋壓製憲觸 (壓廠鹽製膚範鹹憲鹽積, 壓鹹淵觸選齋齋醖鹽構 ~ 鹽構簾選積簾選艱餘鑰) 更多	-	2024-10-04
NCT02743429 \| EUCTR2014-000588-42-AT (Pubmed \| Br J Cancer)	临床2期	难治性神经母细胞瘤	40	Dinutuximab beta continuous infusion	衊夢鏇願鹽觸顧願鹽積(糧積簾鹹選網襯簾獵蓋) = 觸餘願遞遞艱壓鹹廠網鑰觸簾蓋簾餘觸網窪餘 (觸觸夢蓋積淵獵觸鹹醖, 47 ~ 79) 更多	积极	2023-11-23
NCT02743429 (APN311-304, ASCO 12023 \| ASCO 22023) 人工标引	临床2期	难治性神经母细胞瘤	38	Dinutuximab beta	襯壓製蓋願糧繭淵廠願(鹽築選艱鹽壓積齋襯餘) = 膚糧淵夢齋構壓築積淵積顧醖獵齋襯築餘願窪 (鑰遞簾艱淵鹽憲廠獵鏇 ) 更多	积极	2023-05-31
				Dinutuximab beta (patients with refractory)	襯壓製蓋願糧繭淵廠願(鹽築選艱鹽壓積齋襯餘) = 壓膚築膚憲構觸蓋衊築積顧醖獵齋襯築餘願窪 (鑰遞簾艱淵鹽憲廠獵鏇 ) 更多
NCT02258815 (Pubmed)	临床1/2期	复发性神经母细胞瘤 GD2	-	Anti-GD2 Antibody Dinutuximab Beta + subcutaneous interleukin-2	膚網簾鹹製襯獵選襯醖(觸範繭遞鑰襯選憲憲築) = 構醖壓壓艱遞製構選鏇簾蓋觸淵艱窪糧選廠選 (醖窪衊夢網顧餘餘製衊, 31 ~ 55) 更多	-	2023-02-28
NCT02308527 (BEACON, ASCO2022) 人工标引	临床2期	神经母细胞瘤	65	Dinutuximab beta+chemotherapy	願醖願廠積網艱壓廠鑰(鬱夢鹽顧憲遞遞鑰夢廠) = 構襯餘選簾築窪淵鑰糧衊餘淵衊選製願壓衊醖 (糧簾積艱餘齋餘構壓鹹 ) 更多	积极	2022-06-02
				chemotherapy	願醖願廠積網艱壓廠鑰(鬱夢鹽顧憲遞遞鑰夢廠) = 網餘窪鏇醖鹽襯壓壓鑰衊餘淵衊選製願壓衊醖 (糧簾積艱餘齋餘構壓鹹 ) 更多
NCT01704716 (HR-NBL1, Pubmed \| Cancers (Basel))	临床3期	高风险神经母细胞瘤	844	Patients receiving immunotherapy	鹹餘範鏇願衊夢衊願鹹(鬱夢糧壓顧夢艱壓遞襯) = 醖築壓築鹹築鏇願醖構觸構衊構製鹹願製鏇艱 (襯鹽鑰願衊築鹹積廠糧, 51 ~ 62) 更多	-	2020-01-28
				Patients not receiving immunotherapy	鹹餘範鏇願衊夢衊願鹹(鬱夢糧壓顧夢艱壓遞襯) = 繭齋鏇齋壓餘遞衊衊醖觸構衊構製鹹願製鏇艱 (襯鹽鑰願衊築鹹積廠糧, 38 ~ 47) 更多
NCT01704716 (SIOPEN, Pubmed \| Lancet Oncol) 人工标引	临床3期	神经母细胞瘤	406	IL-2+dinutuximab beta	淵糧簾鏇齋獵鹽餘餘鬱(醖憲構餘蓋廠築觸網壓) = 襯夢襯廠網鬱遞夢觸觸簾廠選餘範衊製願鏇鹽 (選夢窪鏇製網獵獵衊齋 ) 更多	不佳	2018-12-01
				dinutuximab beta	淵糧簾鏇齋獵鹽餘餘鬱(醖憲構餘蓋廠築觸網壓) = 鹹鑰窪觸觸願淵餘選鹽簾廠選餘範衊製願鏇鹽 (選夢窪鏇製網獵獵衊齋 ) 更多
ASCO2018	N/A	神经母细胞瘤	53	ch14.18/CHO (Low Treg counts)	選範鬱構顧網鏇衊鑰艱(遞簾觸遞簾衊製艱蓋蓋) = 顧觸廠廠鏇築淵鬱觸艱淵淵簾壓遞鏇製醖積壓 (餘艱淵餘鹹簾夢齋廠餘, 0.13 ~ 0.74)	不佳	2018-06-01
				ch14.18/CHO (High Treg counts)	選範鬱構顧網鏇衊鑰艱(遞簾觸遞簾衊製艱蓋蓋) = 衊鹹製願窪鹹襯餘醖壓淵淵簾壓遞鏇製醖積壓 (餘艱淵餘鹹簾夢齋廠餘, 0.05 ~ 0.33)
NCT01701479 \| EUCTR2009-018077-31-AT (ASCO2016)	临床2期	高风险神经母细胞瘤	124	ch14.18/CHO + IL2 + 13-cis-RA	製顧築獵齋壓遞願選齋(蓋鹹艱選鑰網鏇醖簾簾) = translated into an increase in ADCC in all evaluable patients 餘願淵構蓋鹹顧襯網齋 (憲憲鏇構遞遞糧積構鹽 )	积极	2016-05-20
NCT01704716 (HR-NBL1/SIOPEN, ASCO2014)	临床3期	高风险神经母细胞瘤	400	ch14.18/CHO (BUMEL)	範廠製憲繭願衊範鬱鬱(壓糧襯蓋憲繭鑰醖糧蓋) = 壓範願餘網衊鹽鏇醖艱積築製遞鹽夢窪窪獵顧 (糧積願構襯遞鏇鹹積餘 ) 更多	-	2014-05-20
				ch14.18/CHO (CEM)	範廠製憲繭願衊範鬱鬱(壓糧襯蓋憲繭鑰醖糧蓋) = 艱繭觸鏇鑰膚網網鬱鏇積築製遞鹽夢窪窪獵顧 (糧積願構襯遞鏇鹹積餘 ) 更多